İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

OpenAlex konusu

Sphingolipid Metabolism and Signaling

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 678 eser 15 yazar konusu

Çalışmalar

678 eser

  1. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 stu…

  2. A Placebo Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 stu…

  3. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    Özet henüz yok.

  4. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study 2018
    OpenAlex üst %1 OpenAlex 100.0%

    Özet henüz yok.

  5. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.5%

    Özet henüz yok.

  6. Oral fingolimod in primary progressive multiple sclerosis INFORMS a phase 3 randomised double blind placebo controlled trial 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%

    Özet henüz yok.

  7. Switchable Nile Red Based Probe for Cholesterol and Lipid Order at the Outer Leaflet of Biomembranes 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 97.4%

    Cholesterol and sphingomyelin form together a highly ordered membrane phase, which is believed to play important biological functions in plasma membranes of mammalian cells. Since sphingomyelin is present mainly at the outer leaflet of cell membranes, monitoring its lipid order requires molecular probes capable to bin…

  8. Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.2%

    Chemotherapy is the main strategy for the treatment of cancer. However, the main problem limiting the success of chemotherapy is the development of multidrug resistance. The resistance can be intrinsic or acquired. The resistance phenotype is associated with the tumor cells that gain a cross-resistance to a large rang…

  9. Fingolimod provides long term protection in rodent models of cerebral ischemia 2011
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.3%

    OBJECTIVE: The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced multiple sclerosis clinical trials, decreases reperfusion injury in heart, liver, and kidney. We therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral ische…

  10. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.3%

    Mechanisms that alter protein phosphatase 2A (PP2A)-dependent lung tumour suppression via the I2PP2A/SET oncoprotein are unknown. We show here that the tumour suppressor ceramide binds I2PP2A/SET selectively in the nucleus and including its K209 and Y122 residues as determined by molecular modelling/simulations and si…

  11. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod subgroup analyses of the double blind randomised placebo controlled FREEDOMS study 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.4%

    Özet henüz yok.

  12. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.4%

    Özet henüz yok.

Akademisyenler

15 akademisyen